Guardant Health up 25% premarket on Q2 beat, guidance raise

Guardant Health (NASDAQ:GH) is up 25% premarket on light volume after releasing better-than-expected Q2 results after the close yesterday. Highlights:

Revenue: $54.0M (+178%).

11,875 tests (+77%) reported to clinical customers. 5,285 tests (+112%) reported to biopharmaceutical customers.

Net loss: ($11.6M); loss/share: ($0.13).

2019 guidance: Revenue: $180M – 190M from $145M – 150M.

Previously: Guardant Health EPS beats by $0.22, beats on revenue (Aug. 6)

https://seekingalpha.com/news/3488370-guardant-health-25-percent-premarket-q2-beat-guidance-raise